Drug Price Reform in China's Healthcare System

China’s National Healthcare Security Administration addresses corruption and high drug prices through centralized procurement, reducing costs while maintaining quality. The reform aims to eliminate intermediary markups and streamline distribution channels.

The Chinese healthcare system is undergoing significant transformation in its approach to drug pricing and procurement. This shift comes as the National Healthcare Security Administration (NHSA) of China implements measures to address the long-standing issues of inflated drug prices and corruption in the pharmaceutical sector.

At the core of this reform is the centralized procurement system, which has demonstrated promising results over the past five years. This system effectively eliminates multiple layers of intermediaries that previously contributed to artificial price inflation. According to NHSA’s pricing director Ding Yikai, the inflated drug prices were not benefiting pharmaceutical companies' research and development or quality improvement, but were instead being diverted through corrupt channels.

The centralized procurement system operates through several key mechanisms. First, it creates direct connections between hospitals and pharmaceutical manufacturers, bypassing traditional distribution networks that often involved questionable practices. This streamlined approach has already generated savings of approximately 44 billion yuan (approximately $6.8 billion) in medical insurance funds since 2018.

Healthcare quality assurance remains a critical focus of the reform. The NHSA has established a comprehensive credit evaluation system for pharmaceutical companies participating in centralized procurement. By the end of 2024, 735 companies were rated for trustworthiness, with varying degrees of compliance. This system helps ensure that cost reduction does not compromise drug quality.

The reform also addresses the broader ecosystem of healthcare delivery. The NHSA has reallocated 80% of the savings from centralized procurement to support the development and accessibility of innovative drugs. This strategic reinvestment demonstrates a commitment to advancing medical treatment while maintaining cost efficiency.

Particularly noteworthy is the system’s impact on corruption prevention. The centralized procurement model inherently reduces opportunities for bribery and kickbacks by eliminating multiple transaction points where corruption previously flourished. The NHSA has implemented strict penalties for companies engaging in commercial bribery or bid manipulation, with special attention to those attempting to influence healthcare officials.

The transformation extends beyond mere cost reduction. It represents a fundamental shift in how China’s healthcare system manages pharmaceutical resources, balancing accessibility, affordability, and quality. While some stakeholders initially expressed concerns about potential quality compromises, five years of implementation have demonstrated that maintaining drug quality standards is possible alongside cost optimization.

Moving forward, the NHSA plans to further refine the credit evaluation system and strengthen oversight of pharmaceutical companies. This continuing evolution of the procurement system aims to ensure sustainable access to quality medications while protecting public resources from misuse and corruption.

Next
Previous